Novo Nordisk, Eli Lilly Deny Mangoceuticals Partnership
Novo Nordisk and Eli Lilly reject Mangoceuticals' false partnership claims regarding weight-loss drugs.
/ 345 items
#Healthcare↓
Hims & Hers Expands Into Lab Testing to Boost Preventive Care
Hims & Hers Health launches lab testing with Quest Diagnostics, offering affordable biomarker tests and personalized health plans as part of its preventive care expansion.
FDA Approves Kura's Ziftomenib (Komzifti) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible NPM1 Mutation
The FDA has approved Komzifti for adults facing difficult-to-treat AML linked to a specific NPM1 gene change.
Outlook ONS-5010 BLA Accepted; FDA Target Date Dec 31, 2025
Outlook Therapeutics' potential new treatment, ONS-5010 (LYTENAVA), is under FDA review following a successful BLA resubmission. The decision is expected by December 31, 2025.
Day One Acquires Mersana for $285M to Gain Emi-Le Cancer Drug
Day One is acquiring Mersana Therapeutics for up to $285 million to gain Emi-Le, a promising new drug candidate for adenoid cystic carcinoma, a cancer with few treatment options.
Korro Bio Announces Major Restructuring and Program Shifts
Korro Bio is focusing on new genetic medicines (GalNAc programs) after poor trial results for KRRO-110, pausing its Novo Nordisk partnership, and reducing its staff by 34%.